Key indicators: single-crystal X-ray study; T = 173 K; mean (C-C) = 0.003 Å; R factor = 0.034; wR factor = 0.078; data-to-parameter ratio = 19.9. organic compounds o2182 Lombard et al.
The title compound, C 17 H 27 BrO 5 , DEB, is a derivative of artemisinin which is used in malara therapy. The OR-group at C12 is cis to the CH 3 -group at C11 and axially oriented on ring D which has a chair conformation. The crystal packing is stabilized by several weak intermolecular C-HÁ Á ÁO interactions, which combine to form a C-H-O bonded network parallel to (001).
Related literature
For background to malaria, see: World Health Organisation (2008) . For the effective of artemisinin analogs against malaria, see: Ploypradith (2004) . For the crystal structure of artemisinin, see: Kuhn & Wang (2008) and of dihydroartemisinin (DHA), see: Luo et al. (1984) . Jasinski et al. (2008a) redetermined the structure of DHA as well as characterizing the second polymer of -arteether (Jasinski et al., 2008b) . For the reaction of DEB with amines, see: Li et al. (2000) . For the synthesis of artemisinin hybrids, see: Walsh et al. (2007) ; Basco et al. (2001) ; Grelepois et al. (2005) ; Gupta et al. (2002) . For puckering analysis, see: Cremer & Pople (1975) ; Evans & Boeyens (1989 Table 1 Hydrogen-bond geometry (Å , ). Symmetry codes: (i) Àx þ 1; y À 1 2 ; Àz þ 2; (ii) Àx; y À 1 2 ; Àz þ 2.
Data collection: APEX2 (Bruker, 2005); cell refinement: SAINT (Bruker, 2005); data reduction: SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008) ; program(s) used to refine structure: SHELXL97 (Sheldrick, 2008) ; molecular graphics: ORTEP-3 for Windows (Farrugia, 1997) and SCHAKAL99 (Keller, 1999) ; software used to prepare material for publication: WinGX (Farrugia, 1999) and PLATON (Spek, 2009 Malaria is one of the top three priority diseases of the WHO and is becoming a worldwide threat because of its wide spread resistance to current anti-malaria drugs (World Health Organization, 2008) . Artemisinin and its derivatives currently represent the most effective group of compounds against multidrug-resistant malaria with a rapid onset of action and a short half life. However, when artemisinin analogs are used as monotherapy it results in significant recrudescence (Ploypradith, 2004) . Therefore it is recommended by the WHO that all uncomplicated P. falciparum infections should be treated with an artemisinin-based combination therapy (ACT).
When DHA is prepared from artemisinin by reduction, it exists as a mixture of α-and β-isomers. Luo and co-workers (Luo et al. 1984) determined that these isomers can exist in two conformations of ring D, a half-chair form and a half-boat form. DEB was tested in vitro against Plasmodium falciparum sensitive (D10) and resistant (Dd2) strains, but did not show any improved activity with respect to the reference drug: dihydroartemisinin (DHA).
The title compound, C 17 H 27 BrO 5 or 2-(10β-dihydroartemisinoxy)ethylbromide (DEB), is a derivative of artemisinin.
DEB was synthesized from the reaction of DHA with bromoethanol. DHA was supplied as a mixture of anomers. With the formation of DEB the OR-group at C12 is positioned cis to the CH 3 -group at C11 and axially oriented on ring D. Therefore, DEB can be assigned to the β-chair series. The rings in the title compound have also been previously labeled as rings A, B, These combine to form a C-H-O bonded network parallel to (001).
Experimental
The title compound was prepared as described by Li and co-workers (Li et al., 2000) . The product was recrystallized from methanol using a slow evaporation technique at room temperature with a 71% yield of white needle-like crystals. IC 50 (ng/ml) of the title compound (DEB): D10 = 41.39, Dd2 = 129.47 IC 50 (ng/ml) of Dihydroartemisinin: D10 = 1.45, Dd2 = 0.59.
Refinement
All H atoms were positioned geometrically, and allowed to ride on their parent atoms, with Atom-H bond lengths of 1.00 Å (CH), 0.99 Å (CH 2 ), or 0.98 Å (CH 3 ). Isotropic displacement parameters for these atoms were set to 1.2 times (CH and CH 2 ) or 1.5 times (CH 3 ) U eq of the parent atom. Refinement. Refinement of F 2 against ALL reflections. The weighted R-factor wR and goodness of fit S are based on F 2 , conventional R-factors R are based on F, with F set to zero for negative F 2 . The threshold expression of F 2 > σ(F 2 ) is used only for calculating Rfactors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based on F 2 are statistically about twice as large as those based on F, and R-factors based on ALL data will be even larger.
Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å 2 )
x y z U iso */U eq C1 0.4624 (2) 0.8858 (2) 0.7096 (2) 0.0219 (6) 0.0188 (9) 0.0213 (9) 0.0262 (10) 0.0004 (7) −0.0008 (7) 0.0009 (8) O2 0.0249 (9) 0.0177 (8) 0.0296 (10) −0.0009 (7) −0.0010 (8) −0.0022 (7) O3 0.0239 (9) 0.0236 (10) 0.0228 (9) 0.0051 (7) 0.0001 (7) −0.0055 (8) O4 0.0188 (8) 0.0270 (9) 0.0219 (8) −0.0001 (7) 0.0026 (7) 0.0006 (7) O5 0.0195 (8) 0.0254 (9) 0.0255 (9) −0.0045 (7) 0.0014 (7) 0.0030 (7) Geometric parameters (Å, °) 
